Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in P
Go back to Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in P| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 103.66 +5.44 (5.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $98.22 | 52 Week High | $118.49 | |||
| Open | $99.79 | 52 Week Low | $55.00 | |||
| Day High | $103.71 | P/E | N/A | |||
| Day Low | $99.79 | EPS | $-0.56 | |||
| Volume | 2,204,986 | |||||
